Product Pipeline with Competitive Advantage

CEVEC develops an early-stage pipeline of biopharmaceutical difficult-to-express proteins with commercial attractive markets and well-established biological targets. All molecules target improved biological activity and/or half-live compared to 1st generation molecules and address an unmet need: Either a recombinant version does not yet exist as a therapeutic agent or the recombinant version so far fails to meet therapeutic requirements.

The attractive lead molecule recombinant human Alkaline Phosphatase is being developed as a consortial European project with our Dutch partners Alloksys BV, and Pharmacell BV, and is currently being actively pushed from preclinical to initial clinical PoC, which is expected in 2012.

Other difficult-to-express plasma proteins, like human Alpha Antitrypsin (hAAT), or the first fully human C-1 inhibitor address substantial markets of various hereditary genetic disorders. They are in early preclinical development and open for licensing.